“Global Transplant market set to grow to $45bn by 2024” says new Visiongain report

18 December 2018
Pharma

Visiongain has launched a new pharma report Global Transplant Market Report : Tissue Products, Immunosuppressive Drugs, Preservation Solutions, Tissue Transplant, Organ Transplant, Heart Valve, Vascular Grafts, Bone Grafts, Cornea, Skin Grafts, Bone Marrow, Other Tissues, Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Pancreas Transplant, Other Transplant, Hospitals, Transplant Centres, Other End-Users.

The worldwide rise in the demand for tissue or organs for transplant can be attributed to upsurge in the incidence of acute or chronic diseases. For instance, high blood pressure and diabetes are the foremost causes of end-stage kidney conditions, where kidney transplantation or dialysis is the solitary treatment possibilities to save a patient’s life. As stated by the National Kidney Foundation, there were approximately 122,737 patients in the U.S., who are waiting to receive organs for transplantation in 2014. Thus, there is growing demand for high-end tissue products for the treatment of organ damage or failure, and leukaemia treatment.

The lead analyst of the report commented "Rising number of transplant surgeries, escalating prevalence of chronic diseases, and developing healthcare infrastructure in emerging economies such as China, India, South Africa, Brazil, Mexico, and Indonesia are factors that will drive the demand for transplant products. However, factors such as lack of skilled professionals and high cost of organ transplant surgeries are expected to limit the market growth."

Leading companies featured in the report include AbbVie, Inc., Arthrex, Inc., Medtronic, Novartis AG, Stryker, Teva Pharmaceuticals, Veloxis Pharmaceuticals, Zimmer Biomet

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biological Imaging Reagents Market Report 2021-2031

Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.

13 November 2020

Read

Visiongain Publishes Antihypertensive Drugs Market Report 2021-2031

Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly from last few years. Hypertensive can occur due to consumption of tobacco, too much salt (sodium) and little potassium in your diet, alcohol and to people being overweight or obese.

13 November 2020

Read

Visiongain Publishes Antibacterial Drugs Market Report 2021-2031

The prevalence of bacterial diseases is significantly growing and expected to continuously rise over the forecast period. Number of bacterial diseases cases are increasing, like, bugs biting, including ticks, mosquitoes, lice and from an infected animal, contaminated food or water.

13 November 2020

Read

Visiongain Publishes Topical Drug Delivery Market Report 2020-2030

Delivery of biologics through the transdermal route is anticipated to open new avenues for the manufacturers of topical drugs. Transdermal route provides appropriate and painless self-administration for patients. It overcomes frequent dosing administration, plasma level instability related to oral dosing and injections to uphold constant drug concentrations, and a drug with a short half-life can be supplied effortlessly.

11 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever